The long testimony that Irène Frachon has delivered to the bar by the correctional court of Paris, 16 October, was the occasion of a relentless demonstration of the link between the decision of the Mediator and the development of two serious diseases, potentially life-threatening : valvular heart disease and pulmonary hypertension.
Those eight hours of testimony will also have been the moment where, for the first time, was raised the question of compensation to the victims of this drug product. In particular, through an altercation between the doctor of the CHU of Brest, which led to withdraw of the market…